News | June 01, 2022
NATCO launches first generic version of Nexavar Tablets in the US
The product will be launched by NATCO's commercial partner Viatris.
The product will be launched by NATCO's commercial partner Viatris.
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
The campaign aims to promote an integrated view by combining Ayurveda and Yoga to create harmony not just within the body, but also in our minds
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
Subscribe To Our Newsletter & Stay Updated
